These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 17913545)

  • 1. Systemic but not mucosal immunity induced by AVA prevents inhalational anthrax.
    Klinman DM; Currie D; Lee G; Grippe V; Merkel T
    Microbes Infect; 2007 Oct; 9(12-13):1478-83. PubMed ID: 17913545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge.
    Bielinska AU; Janczak KW; Landers JJ; Makidon P; Sower LE; Peterson JW; Baker JR
    Infect Immun; 2007 Aug; 75(8):4020-9. PubMed ID: 17502384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced early innate and T cell-mediated responses in subjects immunized with Anthrax Vaccine Adsorbed Plus CPG 7909 (AV7909).
    Minang JT; Inglefield JR; Harris AM; Lathey JL; Alleva DG; Sweeney DL; Hopkins RJ; Lacy MJ; Bernton EW
    Vaccine; 2014 Nov; 32(50):6847-54. PubMed ID: 24530403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nasal immunization with anthrax protective antigen protein adjuvanted with polyriboinosinic-polyribocytidylic acid induced strong mucosal and systemic immunities.
    Sloat BR; Cui Z
    Pharm Res; 2006 Jun; 23(6):1217-26. PubMed ID: 16718616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Marked enhancement of the immune response to BioThrax® (Anthrax Vaccine Adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers.
    Rynkiewicz D; Rathkopf M; Sim I; Waytes AT; Hopkins RJ; Giri L; DeMuria D; Ransom J; Quinn J; Nabors GS; Nielsen CJ
    Vaccine; 2011 Aug; 29(37):6313-20. PubMed ID: 21624418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and immunogenicity of single-dose AdVAV intranasal anthrax vaccine compared to anthrax vaccine absorbed in an aerosolized spore rabbit challenge model.
    Krishnan V; Andersen BH; Shoemaker C; Sivko GS; Tordoff KP; Stark GV; Zhang J; Feng T; Duchars M; Roberts MS
    Clin Vaccine Immunol; 2015 Apr; 22(4):430-9. PubMed ID: 25673303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of a vaccine based on protective antigen and killed spores against experimental inhalational anthrax.
    Gauthier YP; Tournier JN; Paucod JC; Corre JP; Mock M; Goossens PL; Vidal DR
    Infect Immun; 2009 Mar; 77(3):1197-207. PubMed ID: 19114543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aerosolized Intratracheal Inoculation of Recombinant Protective Antigen (rPA) Vaccine Provides Protection Against Inhalational Anthrax in B10.D2-Hc
    Song X; Zhang W; Zhai L; Guo J; Zhao Y; Zhang L; Hu L; Xiong X; Zhou D; Lv M; Yang W
    Front Immunol; 2022; 13():819089. PubMed ID: 35154137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trimethyl Chitosan Nanoparticles Encapsulated Protective Antigen Protects the Mice Against Anthrax.
    Malik A; Gupta M; Mani R; Gogoi H; Bhatnagar R
    Front Immunol; 2018; 9():562. PubMed ID: 29616046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advax-adjuvanted recombinant protective antigen provides protection against inhalational anthrax that is further enhanced by addition of murabutide adjuvant.
    Feinen B; Petrovsky N; Verma A; Merkel TJ
    Clin Vaccine Immunol; 2014 Apr; 21(4):580-6. PubMed ID: 24554695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen.
    Boyaka PN; Tafaro A; Fischer R; Leppla SH; Fujihashi K; McGhee JR
    J Immunol; 2003 Jun; 170(11):5636-43. PubMed ID: 12759444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CpG oligonucleotides accelerate and boost the immune response elicited by AVA, the licensed anthrax vaccine.
    Klinman DM
    Expert Rev Vaccines; 2006 Jun; 5(3):365-9. PubMed ID: 16827620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A three-dose intramuscular injection schedule of anthrax vaccine adsorbed generates sustained humoral and cellular immune responses to protective antigen and provides long-term protection against inhalation anthrax in rhesus macaques.
    Quinn CP; Sabourin CL; Niemuth NA; Li H; Semenova VA; Rudge TL; Mayfield HJ; Schiffer J; Mittler RS; Ibegbu CC; Wrammert J; Ahmed R; Brys AM; Hunt RE; Levesque D; Estep JE; Barnewall RE; Robinson DM; Plikaytis BD; Marano N;
    Clin Vaccine Immunol; 2012 Nov; 19(11):1730-45. PubMed ID: 22933399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CpG oligodeoxynucleotides adsorbed onto polylactide-co-glycolide microparticles improve the immunogenicity and protective activity of the licensed anthrax vaccine.
    Xie H; Gursel I; Ivins BE; Singh M; O'Hagan DT; Ulmer JB; Klinman DM
    Infect Immun; 2005 Feb; 73(2):828-33. PubMed ID: 15664922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of non-toxin vaccine adjuvants for their ability to enhance the immunogenicity of nasally-administered anthrax recombinant protective antigen.
    Gwinn WM; Johnson BT; Kirwan SM; Sobel AE; Abraham SN; Gunn MD; Staats HF
    Vaccine; 2013 Mar; 31(11):1480-9. PubMed ID: 23352329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epitope-focused peptide immunogens in human use adjuvants protect rabbits from experimental inhalation anthrax.
    Oscherwitz J; Feldman D; Yu F; Cease KB
    Vaccine; 2015 Jan; 33(3):430-6. PubMed ID: 25454087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sublingual targeting of STING with 3'3'-cGAMP promotes systemic and mucosal immunity against anthrax toxins.
    Martin TL; Jee J; Kim E; Steiner HE; Cormet-Boyaka E; Boyaka PN
    Vaccine; 2017 Apr; 35(18):2511-2519. PubMed ID: 28343781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a novel adjuvanted nasal vaccine: C48/80 associated with chitosan nanoparticles as a path to enhance mucosal immunity.
    Bento D; Staats HF; Gonçalves T; Borges O
    Eur J Pharm Biopharm; 2015 Jun; 93():149-64. PubMed ID: 25818119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bridging non-human primate correlates of protection to reassess the Anthrax Vaccine Adsorbed booster schedule in humans.
    Schiffer JM; Chen L; Dalton S; Niemuth NA; Sabourin CL; Quinn CP
    Vaccine; 2015 Jul; 33(31):3709-16. PubMed ID: 26072016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A CpG-Ficoll Nanoparticle Adjuvant for Anthrax Protective Antigen Enhances Immunogenicity and Provides Single-Immunization Protection against Inhaled Anthrax in Monkeys.
    Kachura MA; Hickle C; Kell SA; Sathe A; Calacsan C; Kiwan R; Hall B; Milley R; Ott G; Coffman RL; Kanzler H; Campbell JD
    J Immunol; 2016 Jan; 196(1):284-97. PubMed ID: 26608924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.